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Summary. Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit 
intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may coun-
terbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol®, 
an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living 
cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii 
LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 
years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol® significantly di-
minished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the 
current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the man-
agement of patients undergoing BP. (www.actabiomedica.it)
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O r i g i n a l  a r t i c l e
Introduction
The human intestinal tract contains a large num-
ber of diverse microbes, some of which are associated 
with the faeces, while others are associated with the 
gut mucosa. Most of these microbes are bacteria and 
constitute a unique and dense ecosystem named mi-
crobiota (1). Many studies investigated human gut 
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microbiota, including the Human Microbiome Project 
in the United States, to define its physiological and 
pathological role (2).
It is well known that antibiotics may significantly 
affect the intestinal microbiota (3). Bowel preparation 
(BP) may also modify critically microbiota (4). BP 
consists of large doses of laxatives to evacuate most if 
not all of the stool from the colon. Typically, such a 
preparation is taken by the patient overnight before 
the procedure, resulting in 10–20 bowel movements, 
most of which are diarrheal stools. Therefore, BP sig-
nificantly affect the colonic ecosystem. In particular, 
polyethylene glycol-type BP causes loss of superficial 
mucus in 96% of patients: it contributes consequently 
to profound alteration of microbiota (5). In addition, 
BP effects vary in health and in disease as it has been 
reported that BP affects various microbiota-related di-
versity metrics in inflammatory bowel disease (IBD) 
and non-IBD samples and the mucosal and luminal 
compartments, differently (4). Overweight also influ-
ences microbiota changes after BP (6). 
The relevance of these concepts relies on the huge 
number of colonoscopies performed worldwide, e.g. 
just 14 millions/year in the United States (7). In ad-
dition, colonoscopy induces also symptoms persistence 
for some days; symptoms can be also so severe as to 
cause the loss of working days (8). These symptoms 
mainly depend on BP-induced microbiota disturbance 
(9). Notably, microbiota changes may persist until one 
month after colonoscopy (10, 11). Therefore, there is 
the need to counterbalance microbiota alteration in a 
short time. In this regard, probiotics may offer a po-
tential therapeutic option to restore the altered gut 
microbiota. Two recent studies provided evidence that 
probiotic may significantly improve both symptoms 
and gut microbiota after BP (12, 13).
Abincol® is an oral nutraceutical containing a 
probiotic mixture with Lactobacillus plantarum LP01 
(1 billion of living cells), Lactobacillus lactis subspecies 
cremoris LLC02 (800 millions of living cells), and Lac-
tobacillus delbrueckii LDD01 (200 millions of living 
cells) and it has been recently placed on the market.
On the basis of this background, an Italian survey 
explored the pragmatic approach of a group of gastro-
enterologists in the management of intestinal dysbiosis 
after BP in clinical practice. Therefore, the aim of the 
current survey was to evaluate the efficacy and safety of 
Abincol® in outpatients after colonoscopy.
Materials and Methods
The current survey was conducted in 83 Italian 
Gastroenterology centers, distributed in the whole It-
aly, so assuring a wide and complete national coverage, 
during the fall-winter 2018-2019. Gastroenterologists 
were asked to recruit all consecutive outpatients un-
dergoing BP for colonoscopy.
Patients were consecutively recruited during the 
specialist visit. The inclusion criteria were: to have the 
indication for colonoscopy, such as presence of intes-
tinal complaints, both genders, and adulthood. Exclu-
sion criteria were to have comorbidities and concomi-
tant medications able to interfere the evaluation of 
outcomes.
All patients signed an informed consent. All the 
procedures were conducted in a real-world setting.
The treatment course lasted 4 weeks. The oral nu-
traceutical Abincol® (Aurora Biofarma, Milan, Italy) 
was taken following the specific indications, such as 
one stick/daily. Patients were visited at baseline (T0), 
and after 4 weeks (T1).
Clinical examination was performed in all patients 
at T0, and T1. The following symptoms were investi-
gated: abdominal pain, abdominal bloating, flatulence, 
and borborygmic. They were evaluated before BP and 
at T1.
These symptoms were assessed as present/absent 
and were scored using a four-point scale (0=absent, 1= 
mild, 2=moderate, 3=severe), but for abdominal pain 
the scale was 5-point (4=very severe). 
A physical examination of stool was performed 
using the Bristol stool form scale (16).
Safety was measured by reporting the occurrence 
of adverse events.
All clinical data were inserted in an internet-plat-
form that guaranteed the patients’ anonymity and the 
findings’ recording accuracy. 
The paired T-test was used. Statistical significance 
was set at p <0.05. Data are expressed as medians and 
1th and 3rd quartiles. The analysis was performed using 
STATA, College Station, Texas, USA. 
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Results
Globally, 2,979 outpatients (1,579 males and 
1,400 females, mean age 56 years) were visited and 
completed the treatment course.
The frequency of symptoms (abdominal pain, 
abdominal bloating, flatulence, and borborygmi) at 
baseline (T0) and at T1 is reported in Table 1 and 2. 
In particular, abdominal pain and abdominal bloating 
were the most common symptoms at baseline. The fre-
quency of both significantly diminished after the treat-
ment course.
Consistently, the severity of the most relevant 
symptoms did significantly diminish after the treat-
ment (Figure 1). In particular, abdominal pain and 
bloating significantly diminished at T1 (p<0.001 re-
spectively for both symptoms).
Table 1. Frequency of patients for each symptom at baseline 
(T0). M=males; F=females, Mean age in years
N=2,979 T0
 n % M/F Mean age
Abdominal pain 2387 80.1% 1256/1131 55
Abdominal bloating 2102 70.6% 1090/1012 56
Flatulence 1936 65.0% 1037/899 56
Borborygmi 1690 56.7% 872/818 56
Table 2. Comparison of proportion of patients with symptoms 
at baseline (T0) and at T1
 T0  T1 
 n n % Diff % p
Abdominal pain 2387 1124 47.1% -52.9% <0.001
Abdominal bloating 2102 1039 49.4% -50.6% <0.001
Flatulence 1936   948 49.0% -51.0% <0.001
Borborygmi 1690   677 40.1% -59.9% <0.001
Figure 1. Symptoms severity at baseline (T0) and at T1. Symptoms’ score scale was 0-3 for all symptoms but abdominal pain (0-4). 
Comparisons were made by paired Wilcoxon test. *= p<0.001
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In addition, stool form significantly improved as a 
normal form (type 3 and 4) was detectable in 36.3% at 
baseline, and in 53.5% at T1 (p<0.001 as linear trend).
The treatment was well tolerated by all patients 
and no clinically relevant adverse event was reported.
Discussion
Drago and colleagues reported relevant and per-
sistent changes in the intestinal bacteria composition 
after colonic lavage (10). Actually, the relative abun-
dance among the different bacterial phyla had reduced 
after the BP, in particular, there was a significant in-
crease in Proteobacteria abundance and a decrease in 
Firmicutes abundance. This intestinal dysbiosis has 
been linked to diarrhea, and more interestingly, it has 
been reported an association between the increase in 
Proteobacteria and the onset of moderate to severe di-
arrhea in children from low-income countries (14). An 
increased frequency of Enterobacteriaceae has been ob-
served immediately after BP (10). It has to be noted 
that Enterobacteriaceae include a number of nosoco-
mial pathogens with considerable antibiotic resistance, 
which may proliferate and act as pathogens when not 
counteracted by the physiological gut microbiota, but 
also act as a clinically relevant antibiotic-resistance 
reservoir in the intestinal environment (15). Moreover, 
Enterobacteriaceae were markedly changed even after 
one month (10). These microbiota changes are associ-
ated with BP-dependent clinical feature. Hence, there 
is the need to improve the impaired gut microbiota af-
ter BP: in this regard, probiotics could be an attractive 
therapeutic strategy. 
The current survey demonstrated that a 4-week 
course of Abincol® was able to significantly improve 
digestive symptoms and stool form. These outcomes 
are consistent with a previous randomized and place-
bo-controlled study showing that a single capsule of a 
probiotic containing 2.5 x 1010 CFUs of L. acidophilus 
NCFM and B. lactis Bi-07 taken daily starting on the 
night after colonoscopy resulted in an earlier resolu-
tion of abdominal pain from 2.78 to 1.99 days (12). 
Nevertheless, a sub-analysis of that study revealed that 
there was no significant difference between groups in 
post-procedural discomfort, bloating nor time to re-
turn of normal bowel function (13). However, a sub-
group analysis of the patients with preexisting symp-
toms showed a reduction in incidence of bloating with 
the use of probiotics. This subset of patients is consist-
ent with our population as presented symptoms before 
BP. 
Therefore, the current survey demonstrated that 
an oral probiotic mixture with Lactobacillus plantarum 
LP01 (1 billion of living cells), Lactobacillus lactis sub-
species cremoris LLC02 (800 millions of living cells), 
and Lactobacillus delbrueckii LDD01 (200 millions of 
living cells) administered for 4 weeks after colonos-
copy was able to significantly reduce intestinal symp-
toms. The significantly improvement of stool form in 
many patients could be considered the indirect proof 
of the mechanism of action of Abincol® as it modi-
fied the intestinal microbiota inducing a physiological 
digestive function.
In addition, Abincol® was safe and well tolerated.
It is conceivable that the present survey can-
not be considered a formal investigative study. Con-
sequently, further studies should be conducted by a 
rigorous methodology, such as designed according to 
randomized-controlled criteria.
On the other hand, the strength of this survey 
is the huge number of enrolled patients and the real-
world setting. The outcomes could therefore mirror the 
facts observable in clinical practice.
In conclusion, the current survey suggests that 
Abincol® may be considered an effective and safe ther-
apeutic option in the management of patients under-
going BP.
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